This is when side effects are most likely
The new GLP-1 ID protocol was developed in response to outcomes observed in a retrospective study published in Obesity Pillars (June 2025), which analyzed 1,131 patients treated through Ivm's virtual GLP-1 program
A GP, pharmacist, or specialist clinician can: Review your current medication list for potential interactions, particularly with diabetes medications, anticoagulants, thyroid treatments, and hormonal contraceptives Assess your nutritional status and advise on appropriate supplementation only where deficiencies are confirmed Monitor for adverse effects such as hypoglycaemia, gastrointestinal disturbance, or unexpected changes in blood pressure or heart rate Refer you to appropriate NHS services , including Tier 3 weight management programmes, if you are seeking structured support for obesity Discuss contraception and family planning , as retatrutide should not be used during pregnancy or breastfeeding
Trapp S, Cork SC
It is unknown whether GLP-1 receptor agonists are associated with thyroid C-cell tumors, including MTC in humans
Compounded tirzepatide requires proper refrigeration to maintain potency